- Home
- CHRS vs ZNTL Comparison
CHRS vs ZNTL Comparison
Compare CHRS & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- ZNTL
- Stock Information
- Founded
- CHRS 2010
- ZNTL 2014
- Country
- CHRS United States
- ZNTL United States
- Employees
- CHRS N/A
- ZNTL N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- CHRS Health Care
- ZNTL Health Care
- Exchange
- CHRS Nasdaq
- ZNTL Nasdaq
- Market Cap
- CHRS 112.5M
- ZNTL 102.2M
- IPO Year
- CHRS 2014
- ZNTL 2020
- Fundamental
- Price
- CHRS $0.76
- ZNTL $1.26
- Analyst Decision
- CHRS Strong Buy
- ZNTL Buy
- Analyst Count
- CHRS 4
- ZNTL 9
- Target Price
- CHRS $5.26
- ZNTL $8.69
- AVG Volume (30 Days)
- CHRS 1.7M
- ZNTL 709.5K
- Earning Date
- CHRS 05-12-2025
- ZNTL 05-14-2025
- Dividend Yield
- CHRS N/A
- ZNTL N/A
- EPS Growth
- CHRS N/A
- ZNTL N/A
- EPS
- CHRS N/A
- ZNTL N/A
- Revenue
- CHRS $272,251,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- CHRS N/A
- ZNTL N/A
- Revenue Next Year
- CHRS N/A
- ZNTL N/A
- P/E Ratio
- CHRS N/A
- ZNTL N/A
- Revenue Growth
- CHRS 19.87
- ZNTL N/A
- 52 Week Low
- CHRS $0.66
- ZNTL $1.01
- 52 Week High
- CHRS $2.43
- ZNTL $13.24
- Technical
- Relative Strength Index (RSI)
- CHRS 36.67
- ZNTL 42.91
- Support Level
- CHRS $0.71
- ZNTL $1.16
- Resistance Level
- CHRS $1.06
- ZNTL $1.33
- Average True Range (ATR)
- CHRS 0.08
- ZNTL 0.09
- MACD
- CHRS -0.03
- ZNTL 0.00
- Stochastic Oscillator
- CHRS 12.44
- ZNTL 27.14
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.